A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Summary

SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is a Phase II, multicenter, open-label study designed to evaluate the safety and efficacy of SHR-1210 with BP102 in subjects who are chemotherapy naive and have Stage IIIB\~IV non-squamous NSCLC. The primary end points are ORR and PFS. In this study, subjects will receive SHR-1210 combined with BP102 until progression or unacceptable toxicity (SHR-1210 or BP102 for a maximum of 2 years).

Timeline

Start

2018-11-30

Primary completion

2020-03-11

Completion

2020-03-11

Drugs

Indications